Basic and clinical perspectivesARNOLD, Rudolf.Digestion. 1996, Vol 57, pp 1-120, issn 0012-2823, 126 p., SUP1Conference Proceedings

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analoguesPOLLAK, M.Digestion. 1996, Vol 57, pp 29-33, issn 0012-2823, SUP1Conference Paper

The role of surgery in patients with advanced midgut carcinoid tumoursAHLMAN, H.Digestion. 1996, Vol 57, pp 86-87, issn 0012-2823, SUP1Conference Paper

The ultimate biochemical diagnosis of gastro-enteropancreatic tumoursÖBERG, K.Digestion. 1996, Vol 57, pp 45-47, issn 0012-2823, SUP1Conference Paper

Interferon-α versus somatostatin or the combination of both in gastro-enteropancreatic tumoursÖBERG, K.Digestion. 1996, Vol 57, pp 81-83, issn 0012-2823, SUP1Conference Paper

Somatostatin analogues and exocrine pancreatic secretionGULLO, L.Digestion. 1996, Vol 57, issn 0012-2823, p. 93, SUP1Conference Paper

The place of octreotide in the medical management of the dumping syndromeSCARPIGNATO, C.Digestion. 1996, Vol 57, pp 114-118, issn 0012-2823, SUP1Conference Paper

A comparison of imaging techniques for the localisation of gastro-enteropancreatic neuroendocrine tumoursCHAYVIALLE, J.-A.Digestion. 1996, Vol 57, pp 54-56, issn 0012-2823, SUP1Conference Paper

Biological aspects of neuroendocrine gastro-enteropancreatic tumoursÖBERG, K.Digestion. 1996, Vol 57, pp 42-44, issn 0012-2823, SUP1Conference Paper

Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disordersFRIESS, H; BÜCHLER, M. W.Digestion. 1996, Vol 57, pp 97-102, issn 0012-2823, SUP1Conference Paper

Modulation of growth of human gastric enterochromaffin-like cellsDELLE FAVE, G; ANNIBALE, B.Digestion. 1996, Vol 57, pp 15-16, issn 0012-2823, SUP1Conference Paper

Somatostatin receptor regulation of gastric carcinoid tumoursTANG, L. H; MODLIN, I. M.Digestion. 1996, Vol 57, pp 11-14, issn 0012-2823, SUP1Conference Paper

Clinical use of somatostatin analogues in paediatric oncologyALBERS, A. R; O'DORISIO, M. S.Digestion. 1996, Vol 57, pp 38-41, issn 0012-2823, SUP1Conference Paper

Somatostatin analogs for the treatment of neuroendocrine tumorsCULLER, Michael D; ÖBERG, Kjell; ARNOLD, Rudolf et al.Cancer metastasis reviews. 2011, Vol 30, issn 0167-7659, S9-S17, SUP1Article

Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotideRUSZNIEWSKI, Philippe; ISH-SHALOM, Sofia; DUCREUX, Michel et al.Neuroendocrinology (Basel). 2004, Vol 80, Num 4, pp 244-251, issn 0028-3835, 8 p.Article

GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curveBRANDT, Andreas; KATSCHINSKI, Martin; ARNOLD, Rudolf et al.American journal of physiology. Endocrinology and metabolism. 2001, Vol 44, Num 2, pp E242-E247, issn 0193-1849Article

Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancerSTOLZ, B; SMITH-JONES, P; ALBERT, R et al.Digestion. 1996, Vol 57, pp 17-21, issn 0012-2823, SUP1Conference Paper

ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors : ENETS Consensus GuidelinesPAVEL, Marianne; GROSSMAN, Ashley; SASANO, Hironobu et al.Neuroendocrinology (Basel). 2010, Vol 91, Num 4, pp 326-332, issn 0028-3835, 7 p.Article

Loss of Nuclear p27 Expression and Its Prognostic Role in Relation to Cyclin E and p53 Mutation in Gastroenteropancreatic Neuroendocrine TumorsGRABOWSKI, Patricia; SCHRADER, Jörg; STURM, Isrid et al.Clinical cancer research (Print). 2008, Vol 14, Num 22, pp 7378-7384, issn 1078-0432, 7 p.Article

Xenin-immunoreactive cells and extractable xenin in neuroendocrine tumors of duodenal originFEURLE, Gerhard E; ANLAUF, Martin; HAMSCHER, Gerd et al.Gastroenterology (New York, NY. 1943). 2002, Vol 123, Num 5, pp 1616-1626, issn 0016-5085Article

The ultimate biochemical diagnosis of neuroendocrine gastro-enteropancreatic tumoursFAISS, S; SCHERÜBL, H; RIECKEN, E. O et al.Digestion. 1996, Vol 57, pp 48-49, issn 0012-2823, SUP1Conference Paper

The use of new somatostatin analogues, lanreotides and octastatin, in neuroendocrine gastro-intestinal tumoursERIKSSON, B; TIENSUU JANSON, E; BAX, N. D. .S et al.Digestion. 1996, Vol 57, pp 77-80, issn 0012-2823, SUP1Conference Paper

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupRINKE, Anja; MÜLLER, Hans-Helge; HARDER, Jan et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4656-4663, issn 0732-183X, 8 p.Article

Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumorsARNOLD, Christian N; NAGASAKA, Takeshi; GOEL, Ajay et al.International journal of cancer. 2008, Vol 123, Num 7, pp 1556-1564, issn 0020-7136, 9 p.Article

Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic systemARNOLD, Christian N; SOSNOWSKRI, Andrea; SCHMITT-GRÄFF, Annette et al.International journal of cancer. 2007, Vol 120, Num 10, pp 2157-2164, issn 0020-7136, 8 p.Article